Promising immunotherapy for prostate cancer

References

• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-1197 .
   Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jun 1;371:424–433.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• McNeel DG, Bander NH, Beer TM, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016;4:92.
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 01;24(19):3089–3094.
   PubMed Web of Science ®Google Scholar
• Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013 Jan;62(1):137–147.
   PubMed Web of Science ®Google Scholar
• GuhaThakurta D, Sheikh NA, Fan LQ, et al. Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 2015 Aug 15;21(16):3619–3630.
   PubMed Web of Science ®Google Scholar
• Podrazil M, Horvath R, Becht E, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015 Jul 20;6(20):18192–18205.
   PubMed Web of Science ®Google Scholar
• Xi HB, Wang GX, Fu B, et al. Survivin and PSMA loaded dendritic cell vaccine for the treatment of prostate cancer. Biol Pharm Bull. 2015;38(6):827–835.
   PubMed Web of Science ®Google Scholar
• Reyes D, Salazar L, Espinoza E, et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer. 2013 Sep 17;109(6):1488–1497.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 01;28(7):1099–1105.
   PubMed Web of Science ®Google Scholar
• Mandl SJ, Rountree RB, Dela Cruz TB, et al. Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy. J Immunother Cancer. 2014;2(1):34.
   PubMedGoogle Scholar
• McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009 Sep 01;27(25):4047–4054.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Minami T, Nozawa M, et al. A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer. Eur Urol. 2016 Jul;70(1):35–41.
   PubMed Web of Science ®Google Scholar
• Inderberg-Suso EM, Trachsel S, Lislerud K, et al. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology. 2012 Aug 1;01(5):670–686.
   Google Scholar
• Lilleby W, Gaudernack G, Brunsvig PF, et al. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunol Immunother. 2017 Jul;66(7):891–901.
   PubMed Web of Science ®Google Scholar
• Wood LV, Fojo A, Roberson BD, et al. TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with stage D0 prostate cancer. Oncoimmunology. 2016;5(8:e1197459.
   Web of Science ®Google Scholar
• Castiello L, Sabatino M, Ren J, et al. Expression of CD14, IL10, and tolerogenic signature in dendritic cells inversely correlate with clinical and immunologic response to TARP vaccination in prostate cancer patients. Clin Cancer Res. 2017 Jul 01;23(13):3352–3364.
   PubMed Web of Science ®Google Scholar
• Kubler H, Scheel B, Gnad-Vogt U, et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer. 2015;3:26.
   PubMed Web of Science ®Google Scholar
• Chudley L, McCann K, Mander A, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother. 2012 Nov;61(11):2161–2170.
   PubMed Web of Science ®Google Scholar
• Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010 Jul-Aug;33(6):639–647.
   PubMed Web of Science ®Google Scholar
• Network NCC. Prostate Cancer (Version 1.2017). 2017. [cited 2017 Jan 28]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017 Apr;71(4):630–642.
   PubMed Web of Science ®Google Scholar
• Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014 Oct 20;32(30):3436–3448.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013 Aug;190(2):429–438.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs. ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 05;312(17):1744–1753.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 05;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Schellhammer PF, Chodak G, Whitmore JB, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013 Jun;81(6):1297–1302.
   PubMed Web of Science ®Google Scholar
• Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007 Jul 01;13(13):3776–3782.
   PubMed Web of Science ®Google Scholar
• Fong L, Carroll P, Weinberg V, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov;106(11). doi:10.1093/jnci/dju268.
   PubMedGoogle Scholar
• Essand M, Vasmatzis G, Brinkmann U, et al. High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate. Proc Natl Acad Sci U S A. 1999 Aug 03;96(16):9287–9292.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, McMannis JD, Bai Y, et al. Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. Cancer Immunol Immunother. 2017 Jun 12;66:1345–1357.
   PubMed Web of Science ®Google Scholar
• Inman S. PROSTVAC Misses Phase III Goal in Prostate Cancer. 2017. [cited 2017 Oct 23]. Available from: http://www.onclive.com/web-exclusives/prostvac-misses-phase-iii-goal-in-prostate-cancer
   Google Scholar
• Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005 May 01;11(9):3353–3362.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006 Feb 15;12(4):1260–1269.
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012 May;13(5):501–508.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Uemura H, Naito S, et al. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate. 2011 Apr;71(5):470–479.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Moriya F, Suekane S, et al. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate. 2012 Jun 01;72(8):834–845.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Moriya F, Suekane S, et al. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. BMC Cancer. 2013 Dec;30(13):613.
   Google Scholar
• Noguchi M, Moriya F, Koga N, et al. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother. 2016 Feb;65(2):151–160.
   PubMed Web of Science ®Google Scholar
• Pang X, Tashiro K, Eguchi R, et al. Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer. Biosci Biotechnol Biochem. 2013;77(4):766–770.
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994 Dec 23;266(5193):2011–2015.
   PubMed Web of Science ®Google Scholar
• Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997 Aug 15;277(5328):955–959.
   PubMed Web of Science ®Google Scholar
• Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol. 1997 Mar 1;158(5):1989–1993.
   PubMed Web of Science ®Google Scholar
• Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565–594.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):700–712.
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017 Jan;35(1):40–47.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293–12297.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016 Aug 16;7(33):52810–52817.
   PubMed Web of Science ®Google Scholar
• Fakhrejahani F, Madan RA, Dahut WL, et al. Avelumab in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2012;61:2161–2170. [cited 35 Suppl]. Available from: http://abstracts.asco.org/199/AbstView_199_192369.html
   Google Scholar
• Karzai F, Madan RA, Owens H, et al. Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2017.
   Web of Science ®Google Scholar
• Jha GG, Gupta S, Tagawa ST, et al. A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol [abstract]. 2017. [cited 37 suppl] Available from http://abstracts.asco.org/199/AbstView_199_188601.html
   Google Scholar
• Graff JN, Drake CG, Beer TM. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research. Urology. 2013 Feb;81(2):381–383.
   PubMed Web of Science ®Google Scholar
• Yu EY, Wu H, Schloss C. Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC). 2017. [cited 2017 Jul 10]. Available from: http://abstracts.asco.org/199/AbstView_199_183773.html
   Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017 Feb 06;23:3711–3720.
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015 Oct 29;373(18):1697–1708.
   PubMed Web of Science ®Google Scholar
• Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998 Aug 21;281(5380):1191–1193.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005 Apr;5(4):263–274.
   PubMed Web of Science ®Google Scholar
• Shen L, Sundstedt A, Ciesielski M, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res. 2015 Feb;3(2):136–148.
   PubMed Web of Science ®Google Scholar
• Sternberg C, Armstrong A, Pili R, et al. Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2016 Aug 01;34(22):2636–2643.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Vogelzang NJ, Budnik N, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015 Apr;16(4):417–425.
   PubMed Web of Science ®Google Scholar
• Aggarwal RR, Beer TM, Weinberg VK, et al. Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: a department of defense prostate cancer clinical trials consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun;13(3):e191–e198.
   PubMed Web of Science ®Google Scholar
• Si T, Guo Z, Hao X. Combined cryoablation and GM-CSF treatment for metastatic hormone refractory prostate cancer. J Immunother. 2009 Jan;32(1):86–91.
   PubMed Web of Science ®Google Scholar
• Cimadamore A, Scarpelli M, Piva F, et al. Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. Future Oncol. 2017 May;13(12):1105–1114.
   PubMed Web of Science ®Google Scholar
• Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01;12(16):1955–1967.
   PubMed Web of Science ®Google Scholar
• Rojas-Martinez A, Manzanera AG, Sukin SW, et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther. 2013 Nov;20(11):642–649.
   PubMed Web of Science ®Google Scholar
• Junghans RP, Ma Q, Rathore R, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016 Oct;76(14):1257–1270.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Noguchi T, Ward JP, Gubin MM, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017 Feb;5(2):106–117.
   PubMed Web of Science ®Google Scholar
• Higano CS, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). 2009 Genitourinary Cancers Symposium 2009 [cited 2017 2 May]. Available from: http://meetinglibrary.asco.org/content/20543-64
   Google Scholar
• Small EJ, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). 2009 [cited 2017 May 2]. Available from: http://meetinglibrary.asco.org/content/20295-64
   Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 02;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18(1):31–41.
   PubMed Web of Science ®Google Scholar
• Madan RA, Bilusic M, Kim JW, et al. A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. J Clin Oncol. 2013 Feb 20;31(6_suppl):102.
   Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015 Aug 5;373:737–746.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein LE, et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. J Clin Oncol. 2017;35(suppl; abstr LBA3).
   Google Scholar
• Boisgerault N, Kottke T, Pulido J, et al. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther. 2013 Aug;21(8):1507–1516.
   PubMed Web of Science ®Google Scholar